Current Clinical Trials
Clinical trials at Joslin Diabetes Center allow patients to take part in the research discovery process.
Good eyesight helps protect you and allows you to enjoy the beauty in the world. At The Beetham Eye Institute at Joslin Diabetes Center, we’re committed to protecting your eyes for a lifetime.
Just because you have diabetes, doesn’t mean your eyes will fail. There are many sophisticated treatments available today that can help protect your sight for years to come. Our specially trained physicians and staff are experts in diagnosing and treating the many forms of diabetic eye disease.
The Beetham Eye Institute offers thoughtful and personalized eye care by specially trained and educated physicians and staff who are recognized experts in diagnosing and treating the many forms of diabetic eye disease.
Our caring staff includes ophthalmologists, optometrists, technicians, medical assistants, image specialists, and researchers.
They are experts in offering:
Even though diabetes is the leading cause of adult-onset blindness, vision loss due to diabetic retinopathy can be prevented.
Joslin Diabetes Center has been at the forefront of diabetes-related eye disease prevention since its inception and has set standards across the world for the treatment and care of eyes. At Joslin, we have developed clinical guidelines that recommend you take a three-pronged approach to preserving your vision:
Diabetic retinopathy is the most common eye disease for people with diabetes. It occurs when the small blood vessels in the eye are damaged by high levels of glucose in the blood. Although there are a variety of treatments to treat diabetic retinopathy, the earlier it is diagnosed, the more effective the treatment. Take charge of your eye health and make sure that an annual eye exam is part of your comprehensive treatment plan.
Diabetic retinopathy occurs when the tiny blood vessels inside the retina — the tissue at the back of the eye that sends images to the brain — become damaged. There are usually no symptoms at this early “nonproliferative” stage. Essentially all people with diabetes will eventually develop some changes in the retina, usually within 20 years of diabetes onset.
In two-thirds of cases, this type of retinopathy progresses to the “proliferative stage,” although research shows that intensive glucose and blood pressure control can delay the onset of disease and slow its progression. In the proliferative stage, the retina forms new vessels in an attempt to circumvent nonfunctioning blood vessels. These new vessels, however, are abnormal, fragile and bleed readily.
If the condition is treated with laser photocoagulation when the abnormal vessels are in their early stages, severe vision loss can be prevented in about 95 percent of cases. The laser scars the retina, causing the vessels to regress, which prevents subsequent bleeding and pulling on the retina. Since the laser destroys some areas of the retina, there may be side effects of treatment — such as reduced side or night vision — but central vision is retained far better than if the patient receives no treatment at all.
Diabetic macular edema, however, is a different story. Diabetes can cause the retinal vessels to leak, leading to swelling of the retina. If this swelling occurs in the small area in the center of the retina called the macula, the condition is called macular edema. Vision can decline because this area of the retina is responsible for central vision. Laser treatment is also used for this condition but is less successful than when used for new vessels. Treatment reduces the chance of vision worsening by only half, and even when successful, is usually not associated with improved vision.
This is why everyone with diabetes should get annual eye checks and keep blood glucose, blood pressure, and cholesterol in good control.
The Beetham Eye Institute at Joslin Diabetes Center is a world leader in research on diabetic eye disease. Our top researchers are making major discoveries that can help clinicians worldwide treat diabetic eye disease and prevent vision loss.
Joslin is involved in nearly every major clinical trial in the treatment and prevention of diabetic retinopathy and macular edema in the United States. Some of our recent clinical trials have evaluated innovative therapies, including:
Clinical trials at Joslin Diabetes Center allow patients to take part in the research discovery process.
New patients receive a complete eye exam, as well as access to the latest diagnostic technology, including:
Most patients receive an evaluation by an ophthalmologist and an optometrist at each visit. If the evaluation shows any eye problems, your doctor will personally discuss the results with you, educate you on your condition, answer questions, and make a plan for treatments and follow-up care.
Should you need treatment, our caring team includes experts in:
As a patient of the Beetham Eye Institute, you may also be considered for participation in one of our many ongoing clinical trials. Clinical trials offer access to the newest treatment approaches for diabetic eye disease.
If you're a new patient at the Beetham Eye Institute, please arrive a half-hour before your appointment to register and bring the following with you:
If you have your eyes dilated during your examination, you should not plan to drive directly afterward.
Eye appointments involve very thorough and delicate examinations. Exams on average last approximately 2½ hours.